InsightfulValue
← Home

Santen Pharmaceutical
Santen Pharmaceutical

Pharma / Ophthalmic pharmaceuticals and eye care


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

Price
Live  
Overview
Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company specializing in ophthalmic treatments. The company was founded in 1890 and is headquartered in Osaka, Japan. Santen focuses on developing, producing and marketing prescription ophthalmic products, over-the-counter eye drops, and medical devices.
History and milestones
Santen was originally founded in 1890 as Kobe Santa Corporation, a wholesaler of Western medicines. In 1917, the company changed its name to Santen Pharmaceutical Co., Ltd. and shifted its focus to ophthalmology.
Throughout the 20th century, Santen developed and marketed various ophthalmic treatments, including solutions for cataracts, dry eye syndrome, glaucoma, and others. In the 1960s and 1970s, the company expanded its global presence, establishing subsidiaries and joint ventures in Europe, North America, and Asia.
In the 1980s, Santen began developing and manufacturing intraocular lenses for cataract surgery. In 1989, the company opened a research and development center in Tsukuba, Japan, to further its innovative treatments and medical devices.
In recent years, Santen has continued to expand its portfolio and global presence through acquisitions and partnerships. In 2010, the company acquired the U.S.-based company, ISTA Pharmaceuticals, to further its presence in the U.S. In 2011, Santen acquired the Japanese company, Ophthalmics Inc., and in 2014, the company established a joint venture with GlaxoSmithKline to develop and commercialize innovative ophthalmic products.
Products and Sectors
Santen specializes in prescription ophthalmic products, over-the-counter eye drops, and medical devices for various eye conditions. The company has a wide portfolio of products targeting various eye diseases, including dry eye syndrome, glaucoma, cataracts, and retinal disorders.
Santen’s key products include Ikervis, a prescription eye drop for the treatment of severe dry eye in Europe and other countries, and Taflotan, a prescription eye drop for the treatment of glaucoma in Europe and Asia.
In addition to pharmaceutical treatments, Santen also produces medical devices, including intraocular lenses, surgical instruments, and diagnostic equipment for cataracts and other eye conditions.
Research and Development
Santen invests a significant portion of its revenue into research and development (R&D). The company has established research facilities in Japan, the U.S., Europe, and China to develop innovative treatments for eye diseases. With over 1,600 employees dedicated to R&D, Santen’s efforts have led to the development of numerous innovative treatments and medical devices.
Sustainability
Santen is committed to sustainability and corporate social responsibility. The company has established initiatives to reduce its environmental impact, promote diversity and inclusion, and contribute to the community through various programs and partnerships.
In 2019, Santen joined the United Nations Global Compact, the world’s largest corporate sustainability initiative, and pledged to align its operations with the Ten Principles of the UN Global Compact in the areas of human rights, labor, environment, and anti-corruption.
Conclusion
Santen Pharmaceutical Co., Ltd. is a leading ophthalmic-focused pharmaceutical company with a long history of developing innovative treatments and medical devices for eye diseases. Through its commitment to R&D and sustainability, Santen remains dedicated to improving the lives of those suffering from eye conditions globally.
What is special about the company?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIGEgZmV3 IHVuaXF1ZS Bhc3BlY3Rz IHRoYXQgc2 V0IHRoZSBT YW50ZW4gUG hhcm1hY2V1 dGljYWwgY2 9tcGFueSBh cGFydCBmcm 9tIG90aGVy IHBoYXJtYW NldXRpY2Fs IGNvbXBhbm llczogPGJy PjEuIEZvY3 VzIG9uIE9w aHRoYWxtb2 xvZ3k6IFNh bnRlbiBzcG VjaWFsaXpl cyBpbiBwaG FybWFjZXV0 aWNhbHMgYW 5kIG1lZGlj YWwgZGV2aW NlcyBmb3Ig b3BodGhhbG 1pYyBkaXNl YXNlcyBhbm QgY29uZGl0 aW9ucy4gVG hpcyBmb2N1 c2VkIGFwcH JvYWNoIGFs bG93cyB0aG VtIHRvIGJl IGFuIGV4cG VydCBpbiBl eWUgaGVhbH RoIGFuZCBw cm92aWRlIG lubm92YXRp dmUgdHJlYX RtZW50cyBm b3IgcGF0aW VudHMgd2l0 aCBleWUgZG lzZWFzZXMg YW5kIGRpc2 9yZGVycy4g PGJyPjIuIE dsb2JhbCBQ cmVzZW5jZT ogU2FudGVu IGlzIGEgZ2 xvYmFsIGNv bXBhbnkgd2 l0aCBhIHN0 cm9uZyBwcm VzZW5jZSBp biBBc2lhLC BFdXJvcGUs IGFuZCB0aG UgVW5pdGVk IFN0YXRlcy 4gVGhpcyBh bGxvd3MgdG hlbSB0byBy ZWFjaCBhIH dpZGVyIG1h cmtldCBhbm QgcHJvdmlk ZSB0aGVpci Bwcm9kdWN0 cyB0byBhIG RpdmVyc2Ug cmFuZ2Ugb2 YgcGF0aWVu dHMgd29ybG R3aWRlLiA8 YnI+My4gQ2 9tbWl0bWVu dCB0byBSZX NlYXJjaCBh bmQgRGV2ZW xvcG1lbnQ6 IFNhbnRlbi BpbnZlc3Rz IGhlYXZpbH kgaW4gcmVz ZWFyY2ggYW 5kIGRldmVs b3BtZW50LC B3aXRoIGEg Zm9jdXMgb2 4gaW1wcm92 aW5nIHBhdG llbnQgb3V0 Y29tZXMgYW 5kIGRldmVs b3Bpbmcgbm V3IHRyZWF0 bWVudHMgZm 9yIGV5ZSBk aXNlYXNlcy 4gVGhleSBo YXZlIGEgZG VkaWNhdGVk IFImRCBjZW 50ZXIgYW5k IGNvbGxhYm 9yYXRpb25z IHdpdGggbG VhZGluZyBy ZXNlYXJjaC BpbnN0aXR1 dGlvbnMuID xicj40LiBT dXN0YWluYW JpbGl0eTog U2FudGVuIG lzIGNvbW1p dHRlZCB0by BzdXN0YWlu YWJpbGl0eS BhbmQgZXRo aWNhbCBidX NpbmVzcyBw cmFjdGljZX MuIFRoZXkg aGF2ZSBpbX BsZW1lbnRl ZCBpbml0aW F0aXZlcyB0 byByZWR1Y2 UgdGhlaXIg ZW52aXJvbm 1lbnRhbCBp bXBhY3QgYW 5kIHByb21v dGUgc29jaW FsIHJlc3Bv bnNpYmlsaX R5LCBzdWNo IGFzIHVzaW 5nIGVjby1m cmllbmRseS BtYXRlcmlh bHMgYW5kIH Byb21vdGlu ZyBkaXZlcn NpdHkgYW5k IGluY2x1c2 lvbiB3aXRo aW4gdGhlIG NvbXBhbnku IDxicj41Li BQYXRpZW50 LUNlbnRyaW MgQXBwcm9h Y2g6IFNhbn RlbiBwdXRz IHRoZSBwYX RpZW50IGF0 IHRoZSBjZW 50ZXIgb2Yg ZXZlcnl0aG luZyB0aGV5 IGRvLCB3aX RoIGEgZ29h bCBvZiBpbX Byb3Zpbmcg dGhlIHF1YW xpdHkgb2Yg bGlmZSBmb3 IgdGhvc2Ug YWZmZWN0ZW QgYnkgZXll IGRpc2Vhc2 VzLiBUaGV5 IHN0cml2ZS B0byBsaXN0 ZW4gdG8gcG F0aWVudHMg YW5kIGhlYW x0aGNhcmUg cHJvZmVzc2 lvbmFscyBh bmQgZGV2ZW xvcCBwcm9k dWN0cyB0aG F0IG1lZXQg dGhlaXIgbm VlZHMuIDxi cj42LiBQYX J0bmVyc2hp cCBhbmQgQ2 9sbGFib3Jh dGlvbjogU2 FudGVuIHBh cnRuZXJzIH dpdGggb3Ro ZXIgY29tcG FuaWVzIGFu ZCBvcmdhbm l6YXRpb25z IHRvIGRldm Vsb3AgbmV3 IHRyZWF0bW VudHMgYW5k IGltcHJvdm UgcGF0aWVu dCBjYXJlLi BUaGV5IGFs c28gY29sbG Fib3JhdGUg d2l0aCBwYX RpZW50IG9y Z2FuaXphdG lvbnMgYW5k IGFkdm9jYW N5IGdyb3Vw cyB0byByYW lzZSBhd2Fy ZW5lc3MgYW JvdXQgZXll IGhlYWx0aC BhbmQgc3Vw cG9ydCBwYX RpZW50cy4=
What the company's business model?
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

VGhlIFNhbn RlbiBQaGFy bWFjZXV0aW NhbCBjb21w YW554oCZcy BidXNpbmVz cyBtb2RlbC Bmb2N1c2Vz IG9uIHJlc2 VhcmNoLCBk ZXZlbG9wbW VudCwgcHJv ZHVjdGlvbi wgYW5kIG1h cmtldGluZy BvZiBwaGFy bWFjZXV0aW NhbHMgYW5k IG1lZGljYW wgZGV2aWNl cyBpbiB0aG Ugb3BodGhh bG1pYyBmaW VsZC4gVGhl aXIgbWFpbi Bwcm9kdWN0 cyBpbmNsdW RlIHByZXNj cmlwdGlvbi BkcnVncywg b3Zlci10aG UtY291bnRl ciBwcm9kdW N0cywgYW5k IG1lZGljYW wgZGV2aWNl cyBmb3IgdH JlYXRtZW50 IG9mIHZhcm lvdXMgZXll IGRpc2Vhc2 VzIGFuZCBj b25kaXRpb2 5zLiBUaGV5 IGFsc28gaG F2ZSBhIHN0 cm9uZyBwcm VzZW5jZSBp biBpbnRlcm 5hdGlvbmFs IG1hcmtldH MgdGhyb3Vn aCBwYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zIHdpdG ggb3RoZXIg cGhhcm1hY2 V1dGljYWwg Y29tcGFuaW VzLiBUaGUg Y29tcGFuee KAmXMgYnVz aW5lc3Mgc3 RyYXRlZ3kg aXMgYmFzZW Qgb24gaW5u b3ZhdGlvbi wgcXVhbGl0 eSwgYW5kIG dsb2JhbCBl eHBhbnNpb2 4gdG8gbWVl dCB0aGUgbm VlZHMgb2Yg cGF0aWVudH MgYW5kIGhl YWx0aGNhcm UgcHJvZmVz c2lvbmFscy 4=
Interesting facts about the company
Santen Pharmaceutical

πŸ“ˆ Want to read more about Santen Pharmaceutical?

Sign up for free or log in

πŸ”“ Unlock our free guide: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvZT Q0aDJFZzFJ VkFZNmYxWW R3Nkwud2Vi cCIgYWx0PS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi IHRpdGxlPS JTYW50ZW4g UGhhcm1hY2 V1dGljYWwi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgU2FudGVu IFBoYXJtYW NldXRpY2Fs PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+TmiBZ b3VyIGZyZW UgY29weSBv ZiA8aT4iVG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcy I8L2k+IGlz IHdhaXRpbm cKICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9wPg oKICAgICAg ICAgICAgIC AgICAgICAg ICAgPCEtLQ ogICAgICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdt YXJnaW4tdG 9wOiAxMnB4 OyBmb250LX NpemU6IDEz cHg7IGNvbG 9yOiAjNDQ0 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBTaWduIH VwIG5vdyBh bmQgZ2V0IG 91ciBmcmVl IGVCb29rIA ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgPG I+VGhlIENo ZWNrbGlzdC BWYWx1ZSBJ bnZlc3Rvci DigJQgQSBT bWFydGVyIF dheSB0byBQ aWNrIFN0b2 NrczwvYj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIC0tPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8IS0tCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xkaXYgc3R5 bGU9J21hcm dpbi10b3A6 IDE2cHg7IG ZvbnQtc2l6 ZTogMTRweD sgY29sb3I6 ICM0NDQ7IG ZvbnQtZmFt aWx5OiAtYX BwbGUtc3lz dGVtLCBCbG lua01hY1N5 c3RlbUZvbn QsIFNlZ29l IFVJLCBSb2 JvdG8sIEhl bHZldGljYS BOZXVlLCBz YW5zLXNlcm lmOyBsaW5l LWhlaWdodD ogMS42Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBI YXZlIHlvdS BoZWFyZCBh Ym91dCBvdX Igc2hvcnQg PHN0cm9uZy BzdHlsZT0n Zm9udC13ZW lnaHQ6IDYw MDsnPkRhaW x5IFZpZGVv IE5ld3NsZX R0ZXI8L3N0 cm9uZz4/Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8YS BocmVmPSdo dHRwczovL3 d3dy5pbnNp Z2h0ZnVsdm FsdWUuY29t L25ld3NsZX R0ZXIucGhw JyB0YXJnZX Q9J19ibGFu aycgc3R5bG U9J2NvbG9y OiAjMDA3Qk ZGOyB0ZXh0 LWRlY29yYX Rpb246IG5v bmU7IGZvbn Qtd2VpZ2h0 OiA1MDA7IG 1hcmdpbi1s ZWZ0OiA2cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBG aW5kIG91dC Btb3JlCiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8L2E+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICAg ICAgICAgIC AgICAtLT4K ICAgICAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgCi AgICAgICAg CiAgICAgIC AgPHNwYW4g Y2xhc3M9J2 JsdXJyZWQt dGV4dCc+Ci AgICAgICAg ICAgIE1TNG dVMkZ1ZEcg VnVJRkJvWV hKdCBZV05s ZFhScFkyIE ZzSUVOdkxp d2cgVEhSa0 xpQmlaVyBk aGJpQnBkSE 1nIGFIVnRZ bXhsSUcgcH ZkWEp1Wlhr ZyBhVzRnU2 1Gd1lXIDRn WVhNZ1lTQj MgYUc5c1pY TmhiRyBVZ1 pISjFaMmRw IGMzUWdhVz RnTVQgZzVN Q3dnZFc1ay BaWElnZEdo bElHIDVoYl dVZ1JuVnIg ZFdoaGNtRW dTMiBsMFlX ZGhkMkVnIF UyaHZkR1Z1 TGogeGljaj R5TGlCSiBi aUF4T1RFNU xDIEJHZFd0 MWFHRnkgWV NCTGFYUmha MiBGM1lTQl RhRzkwIFpX NGdkMkZ6SU cgbHVZMjl5 Y0c5eSBZWF JsWkNCaGJt IFFnY21WdV lXMWwgWkNC VFlXNTBaVy A0Z1VHaGhj bTFoIFkyVj FkR2xqWVcg d2dRMjh1TE NCTSBkR1F1 SUZSb1pTIE JqYjIxd1lX NTUgSUhkaG N5Qm1iMiBO MWMyVmtJRz l1IElIUm9a U0J3Y20gOW tkV04wYVc5 dSBJRzltSU dWNVpTIEJr Y205d2N5Qm ggYm1RZ2Iz Um9aWCBJZ1 pYbGxJR05o IGNtVWdjSE p2WkggVmpk SE11UEdKeS BQak11SUZS dlpHIEY1TE NCVFlXNTAg Wlc0Z2FYTW diMiA1bElH OW1JSFJvIF pTQnNZWEpu WlggTjBJRX BoY0dGdSBa WE5sSUdOdm JYIEJoYm1s bGN5QjAgYU dGMElITnda VyBOcFlXeH BlbVZ6IElH bHVJSFJvWl MgQmtaWFps Ykc5dyBiV1 Z1ZEN3Z2NI IEp2WkhWam RHbHYgYml3 Z1lXNWtJRy AxaGNtdGxk R2x1IFp5Qn ZaaUJ2Y0cg aDBhR0ZzYl dsaiBJSEJv WVhKdFlXIE 5sZFhScFky RnMgY3l3Z2 JXVmthVyBO aGJDQmtaWF pwIFkyVnpM Q0JoYm0gUW diM1psY2kx MCBhR1V0WT I5MWJuIFJs Y2lCbGVXVW cgWTJGeVpT QndjbSA5a2 RXTjBjeTQ4 IFluSStOQz RnVkcgaGxJ R052YlhCaC BibmtnYUdG eklHIEVnYz NSeWIyNW4g SUdsdWRHVn libSBGMGFX OXVZV3dnIG NISmxjMlZ1 WTIgVXNJSG RwZEdnZyBi M0JsY21GMG FXIDl1Y3lC cGJpQnYgZG 1WeUlEWXdJ RyBOdmRXNT BjbWxsIGN5 QmhibVFnY2 0gVm5hVzl1 Y3lCMyBiM0 pzWkhkcFpH IFV1UEdKeV BqVXUgSUZO aGJuUmxidS BLQW1YTWdZ Mjl5IGNHOX lZWFJsSUcg MXBjM05wYj I0ZyBhWE1n ZEc4Z1kyID l1ZEhKcFlu VjAgWlNCMG J5QjBhRyBV Z2QyVnNiQz FpIFpXbHVa eUJ2WmkgQn dZWFJwWlc1 MCBjeUJpZV NCd2NtIDky YVdScGJtY2 cgYVc1dWIz WmhkRyBsMl pTd2dhR2xu IGFDMXhkV0 ZzYVggUjVJ SEJ5YjJSMS BZM1J6SUdG dVpDIEJ6Wl hKMmFXTmwg Y3lCcGJpQj BhRyBVZ1pt bGxiR1FnIG IyWWdiM0Jv ZEcgaGhiRz F2Ykc5biBl UzQ4WW5JK0 5pIDRnVTJG dWRHVnUgSU doaGN5QmhJ SCBOMGNtOX VaeUJqIGIy MXRhWFJ0Wl cgNTBJSFJ2 SUhKbCBjMl ZoY21Ob0lH IEZ1WkNCa1 pYWmwgYkc5 d2JXVnVkQy B3Z2FXNTJa WE4wIGFXNW 5JRzkyWlgg SWdNakFsSU c5bSBJR2ww Y3lCeVpYIF psYm5WbElH bHUgSUhSb1 pTQmtaWCBa bGJHOXdiV1 Z1IGRDQnZa aUJ1WlggY2 djSEp2WkhW aiBkSE1nWV c1a0lIIFJs WTJodWIyeH YgWjJsbGN5 NDhZbiBJK0 55NGdWR2hs IElHTnZiWE JoYm4ga2dh WE1nYTI1di BkMjRnWm05 eUlHIGwwY3 lCbGVIQmwg Y25ScGMyVW dhVyA0Z2RH aGxJSFJ5IF pXRjBiV1Z1 ZEMgQnZaaU JuYkdGMSBZ Mjl0WVN3Z1 pIIEo1SUdW NVpTQmsgYV hObFlYTmxM QyBCaGJtUW diM1JvIFpY SWdaWGxsSU cgUnBjMjl5 WkdWeSBjeT RnU1hRZ1lX IHh6YnlCdl ptWmwgY25N Z1lTQnlZVy A1blpTQnZa aUJ6IGRYSm 5hV05oYkMg QndjbTlrZF dOMCBjeUJt YjNJZ1kyIE YwWVhKaFkz UWcgWVc1a0 lHZHNZWCBW amIyMWhJSE 4xIGNtZGxj bWxsY3kgND hZbkkrT0M0 ZyBVMkZ1ZE dWdUlHIGho Y3lCeVpXTm wgYVhabFpD QnVkVyAxbG NtOTFjeUJo IGQyRnlaSE 1nWVcgNWtJ R0ZqWTI5cy BZV1JsY3lC bWIzIElnYV hSeklHTnYg YlcxcGRHMW xibiBRZ2RH OGdZMjl5IG NHOXlZWFJs SUggTnZZMm xoYkNCeSBa WE53YjI1em FXIEpwYkds MGVTd2cgYz NWemRHRnBi bSBGaWFXeH BkSGtzIElH RnVaQ0JsZE cgaHBZMkZz SUdKMSBjMm x1WlhOeklI IEJ5WVdOMG FXTmwgY3k0 OFluSStPUy A0Z1NXNGdZ V1JrIGFYUn BiMjRnZEcg OGdhWFJ6SU hCbyBZWEp0 WVdObGRYIF JwWTJGc0lI QnkgYjJSMV kzUnpMQyBC VFlXNTBaVz RnIFlXeHpi eUJ2Wm0gWm xjbk1nWVNC eSBZVzVuWl NCdlppIEJ1 YjI0dGNHaG ggY20xaFky VjFkRyBsal lXd2djSEp2 IFpIVmpkSE 1zSUcgbHVZ MngxWkdsdS BaeUJqYjI1 MFlXIE4wSU d4bGJuTmwg Y3l3Z1pYbG xJRyBOaGNt VWdjM1Z3IG NHeGxiV1Z1 ZEggTXNJR0 Z1WkNCdCBa V1JwWTJGc0 lHIFJsZG1s alpYTXUgUE dKeVBqRXdM aSBCRVpYTn dhWFJsIElH bDBjeUJuYk cgOWlZV3dn YzNWaiBZMl Z6Y3l3Z1Uy IEZ1ZEdWdU lISmwgYldG cGJuTWdZUy BCbVlXMXBi SGt0IGNuVn VJR052Ylgg QmhibmtnZD JsMCBhQ0Iw YUdVZ1ptID kxY25Sb0lH RnUgWkNCbW FXWjBhQyBC blpXNWxjbU YwIGFXOXVj eUJ2WmkgQj BhR1VnYjNK cCBaMmx1WV d3Z1ptIDkx Ym1SbGNuTW cgYzNScGJH d2dhVyA1Mm IyeDJaV1Fn IGFXNGdkR2 hsSUcgSjFj Mmx1WlhOei BMaUJVYUds eklHIGhoY3 lCb1pXeHcg WldRZ2RHOG diVyBGcGJu UmhhVzRnIF lTQnpkSEp2 Ym0gY2djMl Z1YzJVZyBi MllnZEhKaF pHIGwwYVc5 dUxDQmogYj IxdGFYUnRa VyA1MElIUn ZJR1Y0IFky VnNiR1Z1WT IgVXNJR0Z1 WkNCayBaV1 JwWTJGMGFX IDl1SUhSdk lIQmggZEds bGJuUWdZMi BGeVpTND0K ICAgICAgIC A8L3NwYW4+ CiAgICAgIC AgCiAgICAg ICAg
See Company Q&A
Santen Pharmaceutical

πŸ“Š Get full analytics about Santen Pharmaceutical

Sign up for free or log in

πŸ“˜ Claim your free eBook: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal